author-photo

Kati Maharry

Ohio State University
Alliance for Clinical Trials in Oncology

90

Papers

7354

Citations

Citation Trend

Filter By

Papers (61) Sort By

Journal Conference Others

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

2019 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (416)
BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer

2019 Asia-pacific Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (101)
MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene

2018 Head and Neck Pathology
Show All
- Source
- Cite
- Save
Citations (8)
O-027BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (11)
BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia

2015 Leukemia
Show All
- Source
- Cite
- Save
Citations (72)
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics.

2015 Cell Research
Show All
- Source
- Cite
- Save
Citations (195)
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

2014 Cancer
Show All
- Source
- Cite
- Save
Citations (25)